Cargando…

Increased plasma sVCAM-1 is associated with severity in IgA nephropathy

BACKGROUND: A considerable proportion of IgAN patients present with histological vasculitic/crescentic lesions in glomeruli, indicating activation of vascular inflammation. Using sVCAM-1, a well-proven marker for endothelial injury under inflammatory processes, we investigated vascular injury and it...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Li, Shi, Sufang, Liu, Lijun, Lv, Jicheng, Zhang, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557193/ https://www.ncbi.nlm.nih.gov/pubmed/23336423 http://dx.doi.org/10.1186/1471-2369-14-21

Ejemplares similares

Zonulin, as a marker of intestinal permeability, is elevated in IgA nephropathy and IgA vasculitis with nephritis
por: Li, Qianqian, et al.
Publicado: (2022)

Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy
por: Cai, Qingqing, et al.
Publicado: (2017)

The Role of Complement in Microangiopathic Lesions of IgA Nephropathy
por: Li, Jingyi, et al.
Publicado: (2022)

Clinical and pathological characteristics in elderly patients with IgA nephropathy
por: Zhang, Yongji, et al.
Publicado: (2023)

Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy
por: Zhao, Yanfeng, et al.
Publicado: (2015)

Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy
por: Dong, Yaping, et al.
Publicado: (2023)

Urinary CXCL1: A Novel Predictor of IgA Nephropathy Progression
por: Zhao, Yanfeng, et al.
Publicado: (2015)

Synergistic Effect of Mesangial Cell-Induced CXCL1 and TGF-β1 in Promoting Podocyte Loss in IgA Nephropathy
por: Zhu, Li, et al.
Publicado: (2013)

Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy
por: Wang, Manliu, et al.
Publicado: (2019)

The predictive value and response to immunosuppressive therapy of IgA nephropathy patients with crescents in a large retrospective Chinese cohort
por: Guo, Yingman, et al.
Publicado: (2023)

Case Report: A Pathogenic Missense Variant of WT1 Cosegregates With Proteinuria in a Six-Generation Chinese Family With IgA Nephropathy
por: Li, Qianqian, et al.
Publicado: (2022)

Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy
por: Zhai, Ya-Ling, et al.
Publicado: (2016)

A validation study of crescents in predicting ESRD in patients with IgA nephropathy
por: Zhang, Xiaoyan, et al.
Publicado: (2018)

Complement Activation Is Associated With Crescents in IgA Nephropathy
por: Wang, Zi, et al.
Publicado: (2021)

Safety Evaluation of COVID-19 Vaccine in Patients With IgA Nephropathy or IgA Vasculitis Nephritis
por: Zan, Jincan, et al.
Publicado: (2022)

Circulating serum sVCAM-1 concentration in advanced ovarian cancer patients: correlation with concentration in ascites
por: Jakimovska, Marina, et al.
Publicado: (2014)

High preoperative serum sVCAM-1 concentration as a predictor of early ovarian cancer recurrence
por: Jakimovska, Marina, et al.
Publicado: (2020)

The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression
por: Zhao, Na, et al.
Publicado: (2012)

Propensity of IgA to self-aggregate via tailpiece cysteine-471 and treatment of IgA nephropathy using cysteamine
por: Xie, Xinfang, et al.
Publicado: (2021)

Glomerular C4d Deposition and Kidney Disease Progression in IgA Nephropathy: A Systematic Review and Meta-analysis
por: Jiang, Yuanyuan, et al.
Publicado: (2021)

Upregulation of sICAM-1 and sVCAM-1 Levels in the Cerebrospinal Fluid of Patients with Schizophrenia Spectrum Disorders
por: Meixensberger, Sophie, et al.
Publicado: (2021)

Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy
por: Zhou, Jingjing, et al.
Publicado: (2014)

Flaxseed Prevents Leukocyte and Platelet Adhesion to Endothelial Cells in Experimental Atherosclerosis by Reducing sVCAM-1 and vWF
por: Haliga, Raluca Ecaterina, et al.
Publicado: (2013)

Circulating Vascular Cell Adhesion Molecule-1 (sVCAM-1) Is Associated With Left Atrial Remodeling in Long-Distance Runners
por: Contreras-Briceño, Felipe, et al.
Publicado: (2021)

Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management
por: Selvaskandan, Haresh, et al.
Publicado: (2020)

Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy
por: Chen, Pei, et al.
Publicado: (2018)

Immune Characteristics of IgA Nephropathy With Minimal Change Disease
por: Li, Huixian, et al.
Publicado: (2021)

Concurrent IgA Nephropathy and Membranous Nephropathy, Is It an Overlap Syndrome?
por: He, Jia-Wei, et al.
Publicado: (2022)

Role of telitacicept in the treatment of IgA nephropathy
por: Wu, Lijun, et al.
Publicado: (2023)

The Role of IgA in the Pathogenesis of IgA Nephropathy
por: Perše, Martina, et al.
Publicado: (2019)

Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy
por: Zhao, Yan-feng, et al.
Publicado: (2017)

The genetic variants at the HLA-DRB1 gene are associated with primary IgA nephropathy in Han Chinese
por: Jiyun, Yang, et al.
Publicado: (2012)

Corrigendum: Concurrent IgA nephropathy and membranous nephropathy, is it an overlap syndrome?
por: He, Jia-Wei, et al.
Publicado: (2023)

IgA Vasculitis and IgA Nephropathy: Same Disease?
por: Pillebout, Evangeline
Publicado: (2021)

Race/ethnicity and disease severity in IgA nephropathy
por: Hall, Yoshio N, et al.
Publicado: (2004)

Sulodexide in IgA nephropathy
Publicado: (2013)

Experimental IgA nephropathy
Publicado: (1979)

T lymphocytes in IgA nephropathy
por: Tang, Yuyan, et al.
Publicado: (2020)

Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports
por: Tota, Maciej, et al.
Publicado: (2023)

Increased Lifetime Risk of ESRD in Familial IgA Nephropathy
por: Shi, Manman, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pfdfbc6blatbdfgl1jhqenqugp